Abstract:Introduction: Genomic scale copy number, methylation, and fragmentation aberrations are proven genetic and epigenetic biomarkers of circulating tumor DNA (ctDNA). We developed a novel cell-free DNA (cfDNA) methylome sequencing assay that allows for integrative analysis of these genomic features for sensitive detection of multiple types of cancer. Methods: Whole methylome sequencing (WMS) libraries were generated from enzymatically converted cfDNA. Low-pass (~2X) paired-end NGS sequencing was performed on WMS libraries and paired whole genome sequencing (WGS) libraries of unconverted cfDNA for technical comparison and analytical validation. For development of cancer detection models, we profiled the genome-wide methylation density (MD), fragment size index (FSI), fragment end motif (motif) and chromosome instability (CIN) based on WMS data from a discovery cohort of 352 healthy controls and 559 newly diagnosed cancer patients (45 breast, 105 colorectal, 44 esophageal, 79 gastric, 79 liver, 110 lung, 83 pancreatic, and 14 others), 34.5% of which were at stage I or II. Machine learning models, including KNN, SVM, LR, GBDT, and random forest were trained and tested for individual biomarker types, with a final ensemble classifier to integrate all biomarkers. Performance of the predictive model was confirmed on an independent validation cohort consisting of 145 healthy controls and 236 cancer patients (21 breast, 45 colorectal, 18 esophageal, 35 gastric, 34 liver, 47 lung, and 36 pancreatic), among which 31.8% were at early stages (I or II). Results: WMS and WGS data from 512 cfDNA samples showed high concordance in CIN (R=0.988, 95% CI: 0.986-0.990) and FSI (R=0.961, 0.954-0.967) profiles. On the independent validation cohort, the optimal model selected for each of individual genomic features achieved following area under the ROC curve (AUC) values for cancer detection: MD-KNN, 0.830 (0.789-0.870); FSI-SVM, 0.904 (0.874-0.933); motif-SVM, 0.943 (0.920-0.966); and CIN-PAscore, 0.812 (0.770-0.854). The ensemble classifier based on linear SVM outperformed individual biomarkers, with an AUC value of 0.952 (0.934-0.971), which translated to, at 95% specificity, detection sensitivity of 66.7% for breast, 77.8% for colorectal, 83.3% for esophageal, 62.9% for gastric, 82.4% for liver, 66.0% for lung, and 77.8% for pancreatic cancers. Noteworthily, the overall sensitivity on early-stage cancer was 74.7%. Conclusions: These results demonstrate the first proof of principle on the feasibility of integrating multiple genomic cancer markers on the same WMS technical platform. Low-pass WMS on plasma cfDNA from 10ml of blood with integrative multimodal analysis of methylation, fragmentation, and CNV profiles yields in satisfactory sensitivity and specificity for detection of multiple types of cancer, warranting a forthcoming prospective study to further assess its clinical performance in a larger cohort. Citation Format: Yulong Li, Fenglong Bie, Fengwei Tan, Tiancheng Han, Shunli Yang, Fang Lv, Peiyao Nie, Qi Zhang, Yuanyuan Hong, Zhijie Wang, Ji He, Weizhi Chen, Liang Zhao, Shugeng Gao. Multimodal analysis of plasma cell-free DNA methylome for sensitive multi-cancer detection [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 5150.

A computational framework to unify orthogonal information in DNA methylation and copy number aberrations in cell-free DNA for early cancer detection

Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization

An Ultrasensitive Method for Noninvasive Pan-Cancer Early Detection Based on Targeted Methylation Sequencing of Cell-Free DNA.

A Fragment-Based Algorithm for Identifying Pan-Cancer Differential Methylation Markers from Cfdna.

An ultrasensitive approach for cancer screening and tissue of origin prediction based on targeted methylation sequencing of cell-free DNA.

Abstract 5150: Multimodal analysis of plasma cell-free DNA methylome for sensitive multi-cancer detection

A novel artificial intelligence-enhanced electrochemical method for rapid methylation detection in cfDNA: Advancing multi-cancer early diagnosis.

Simultaneous analysis of mutations and methylations in circulating cell-free DNA for hepatocellular carcinoma detection

Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA

Development of a cfDNA based trans-omics approach for early cancer detection

A Computational Framework To Simultaneously Quantify Dna Methylation, Somatic Copy Number Alternation And Dna Heterogeneity From Low Coverage Plasma Circulating Dna Sequencing

Perspective on New Cell-Free DNA Technologies for Early Cancer Detection.

Early cancer detection using low-coverage whole-genome sequencing of cell-free DNA fragments.

Whole-genome bisulfite sequencing analysis of circulating tumour DNA for the detection and molecular classification of cancer

Early detection of colorectal adenocarcinoma by decoding epigenetic and DNA fragmentation fingerprints of plasma cell-free DNA.

Cost-effective methylome sequencing of cell-free DNA for accurately detecting and locating cancer

High-sensitive Multi-Cancers Early Detection for 8 Cancer Types by Cell-Free DNA Targeted Methylation Sequencing: A Retrospective Cohort Study.

Abstract 6697: Deep learning algorithm for cancer detection using multimodal characteristics of whole methylome sequencing of cf-DNA

Multi-cancer detection and tissue of origin determination based on 5-hydroxymethylcytosine biomarkers in circulating cell-free DNA.

Genome-wide cell-free DNA methylation analyses improve accuracy of non-invasive diagnostic imaging for early-stage breast cancer

CancerScreen: A Novel Ultrasensitive Liquid Biopsy for Early-Stage Cancer Detection by Ctdna Duplex Sequencing and Tissue of Origin Identification with Supervised Machine Learning.